*MIC50, 50% MIC; MIC90, 90% MIC; GM, geometric mean; S, susceptible; I, intermediate; R, resistant; –, no intermediate resistance values for these antimicrobial drugs, according to Clinical and Laboratory Standards Institute definitions.
Response to 2,4-D for each of these lines was as expected, with tir1 ibr5 (HS AXR3NT-GUS) showing enhanced resistance compared to the intermediate resistance of either parent.
Strains with intermediate resistance were considered resistant for the purpose of these analyses.
Of the nine samples positive for S. pneumoniae serotype 19A, 77.8% (7/9) were sensitive to penicillin and intermediate resistance was observed for 22.2% (2/9) samples.
For the Rega scores, we used the weighted score suggested by Rega, which uses the following changes: NNRTI were scored 0.25 (with the exception of etravirine with a score of 0.5) for intermediate resistance, and ritonavir-boosted PI were scored 0.75 and 1.5 for intermediate resistance and susceptible, respectively.
Again, the variance of the progeny across years varied most for phenotypes with intermediate resistance (see Supplemenary Figure S1 for within year variation).
Azithromycin breakpoints for intermediate resistance and resistance were > 0.25 - ≤ 0.5 μg/ml and > 0.5 μg/ml respectively [ 21].
Furthermore, isolates that expressed phenotypic resistance to oxacillin were screened for intermediate resistance to vancomycin and teicoplanin using the E-test macrodilution method [ 28].
Using the Clinical and Laboratory Standards Institute (CLSI) guidelines, penicillin breakpoints for intermediate resistance and resistance were > 0.06 ― ≤ 2 μg/ml and >2 μg/ml respectively [ 21].
